Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Cervical pessary didn’t prevent preterm birth in selected women

Key clinical point: Among women with twin pregnancy and a short cervix, the Arabin cervical pessary does not significantly affect the likelihood of preterm birth or a composite measure of adverse neonatal outcomes.

Major finding: Spontaneous preterm birth occurred in 18% of 250 patients who received an Arabin pessary, compared with 21% of 253 patients who received standard care. The adjusted odds ratio, 0.87, was not statistically significant. In subgroup analyses, there was no significant benefit. A composite measure of adverse neonatal outcomes did not significantly differ between the groups.

Study details: A randomized, open-label trial that included 503 women with twin pregnancy and a cervical length of 35 mm or less.

Disclosures: STOPPIT-2 was funded by the National Institute for Health Research (NIHR) in the United Kingdom. Dr. Norman chaired the UK National Institute for Health and Care Excellence guidelines on preterm labor and birth in 2015. In addition, Dr. Norman was a member of a GlaxoSmithKline data safety and monitoring group for a trial of a preterm birth prevention agent, has consulted for Dilafor, and has received research grants for preterm birth prevention from the U.K. Medical Research Council, NIHR, and Tommy’s: Together, for every baby charity.


Norman JE et al. Am J Obstet Gynecol. 2020 Jan;222(1):S756. Abstract LB 1.